Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 75.1% from a year ago
Short-term investments stood at $398.73M at the end of Q1 FY2026, up 75.1% from a year earlier and down 8.9% from the prior quarter.
Context
- Short-term investments amounted to 80.1% of total assets at the end of Q1 FY2026, up 4.7 pp from a year earlier.
- Short-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +75.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 437.89M USD
- Year-over-year change
- +76.2%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 437.89M | +76.2% |
| FY2024 | 2024-12-31 | 248.48M | +221.4% |
| FY2023 | 2023-12-31 | 77.31M | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 short-term investments of $398.73M is the highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +75.1% is the 3rd highest of 6, against a peer median of +34.4%.
- Short-term investments amounts to 80.1% of total assets for RAPP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $398.73M | +75.1% | — | 80.1% |
| Sep 2026 | $383.47M | +226.0% | +84.0% | 29.2% | |
| Mar 2026 | $254.41M | +504.2% | — | 60.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $226.17M | +34.4% | +65.0% | 86.5% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $44.96M | — | — | 11.4% |
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | -100.0% | +28.6% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $0 | +34.4% | +65.0% | 0.0% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.